Merck + Co., Inc.

Jack A Schmidt

Sander G Mills

Malcolm MacCoss

William K Hagmann

Philippe L Durette

Richard A Mumford

Guadalupe A Limjuco

Patricia M Cameron

Gail A Van Riper

Compounds of Formula I are antagonists of VLA-4 and/or &#x3b1;&#x3b2;, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

Heterocyclic amide compounds as cell adhesion inhibitors

Human interleukin-1 (IL-1) charged species (pI 6.8, 6.0, 5.4 and 5.2) are separated and purified by a rapid and efficient two or three stage chromatographic process. Interleukin-1 species present in concentrated culture fluid from stimulated human mononuclear cells are separated and partially purified by anion exchange high performance liquid chromatography. The pI 5.4 and 5.2 species in addition are partially purified by HPLC gel filtration chromatography. Each of the individual IL-1 species are then finally purified by reverse phase high performance liquid chromatography. This process results in homogenously pure pI 6.8, pI 5.4 and pI 5.2 species while the pI 6.0 species is isolated in a substantially pure form.

Purification of human interleukin-1 species

Growing community of inventors

Green Brook, NJ, United States of America

Jack A Schmidt